New drug treatment combined with standard therapy for newly diagnosed brain cancer

This trial is testing whether a drug called Cetuximab, delivered directly into the blood vessels that feed a brain tumor, can work better when combined with standard chemotherapy and radiation therapy. The medication targets a specific protein called EGFR that is often overactive in glioblastoma, the most common type of primary brain cancer. Researchers hope this approach will improve survival and quality of life for people newly diagnosed with this disease.

Glioblastoma is an aggressive brain cancer with poor outcomes—the average survival is about one year, even with current treatments. This trial exists because standard chemotherapy and radiation alone have not been enough to significantly improve survival rates, and researchers believe delivering the medication directly to the tumor may be more effective and cause fewer side effects.